Wall Street brokerages forecast that Aevi Genomic Medicine Inc (NASDAQ:GNMX) will post earnings per share of ($0.10) for the current quarter, according to Zacks. Zero analysts have made estimates for Aevi Genomic Medicine’s earnings. Aevi Genomic Medicine posted earnings per share of ($0.14) in the same quarter last year, which suggests a positive year-over-year growth rate of 28.6%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 15th.
On average, analysts expect that Aevi Genomic Medicine will report full-year earnings of ($0.27) per share for the current fiscal year. For the next financial year, analysts expect that the firm will report earnings of ($0.18) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Aevi Genomic Medicine.
Aevi Genomic Medicine (NASDAQ:GNMX) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.03.
Shares of GNMX stock remained flat at $$0.19 on Friday. The stock had a trading volume of 455,617 shares, compared to its average volume of 3,719,725. The company has a market capitalization of $11.96 million, a P/E ratio of -0.38 and a beta of 0.73. Aevi Genomic Medicine has a 12 month low of $0.15 and a 12 month high of $1.40. The company’s 50 day simple moving average is $0.18.
An institutional investor recently raised its position in Aevi Genomic Medicine stock. Virtu Financial LLC lifted its position in shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 675.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 278,958 shares of the biotechnology company’s stock after buying an additional 242,994 shares during the period. Virtu Financial LLC owned about 0.43% of Aevi Genomic Medicine worth $55,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.45% of the company’s stock.
Aevi Genomic Medicine Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.
Featured Story: How is a price target determined?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.